Teva Pharma (TEVA) Tops Q2 EPS by 14c; Raises Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/28/2026
- Wall St declines as oil spikes after Trump rejects Iran peace proposal
- S&P 500 breadth hits lowest level since dot-com bubble, Goldman says
- Nvidia’s AI dominance funds historic $150 billion buyback
- MongoDB stock drops 15% as CEO Desai resigns for Meta
- Jefferies cuts Roblox to Underperform, says rally is too optimistic
- Bloom Energy shares fall on Oracle project halt
- Oppenheimer sees AI software winners as focus shifts to ROI
- Exclusive-Activist Jana pushes Fiserv to accelerate cost cuts and tap Palantir
- Cantor Fitzgerald Starts Lexicon Pharmaceuticals (LXRX) at Overweight
- Arm Holdings falls as CFO stock sale weighs on sentiment
Teva Pharma (TEVA) PT Raised to $25 at Credit Suisse
August 3, 2018 9:02 AM EDTCredit Suisse raised its price target on Teva Pharma (NYSE: TEVA) to $25.00 (from $23.00) while maintaining a Outperform rating.
... MoreTeva Pharma (TEVA) PT Raised to $23 at Barclays
August 3, 2018 5:14 AM EDTBarclays raised its price target on Teva Pharma (NYSE: TEVA) to $23.00 (from $20.00) while maintaining a Equalweight rating.
... More